Journal article · 2016 · Open access

Marketing Authorization of Medicines Approved In Eu Via “Adaptive Pathway”: Consequences on The Egyptian Public Health

S.R. Ibrahim

Value in Health, 19(3), A289–A290 · Published 1 May 2016 · DOI 10.1016/j.jval.2016.03.749

Open full textCite this paper

In brief

“Marketing Authorization of Medicines Approved In Eu Via “Adaptive Pathway”: Consequences on The Egyptian Public Health” is a 2016 journal article by S.R. Ibrahim, published in Value in Health. OpenAlex counts 0 citations as of 19 November 2026. It is open access: the full text is free to read at Value in Health.

Citations
0
Authors
1

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Ibrahim, S. (2016). Marketing Authorization of Medicines Approved In Eu Via “Adaptive Pathway”: Consequences on The Egyptian Public Health. Value in Health, 19(3), A289–A290. https://doi.org/10.1016/j.jval.2016.03.749

MLA 9

Ibrahim, S.R. “Marketing Authorization of Medicines Approved In Eu Via “Adaptive Pathway”: Consequences on The Egyptian Public Health.” Value in Health, vol. 19, no. 3, 2016, pp. A289–A290. https://doi.org/10.1016/j.jval.2016.03.749.

Chicago

Ibrahim, S.R. 2016. “Marketing Authorization of Medicines Approved In Eu Via “Adaptive Pathway”: Consequences on The Egyptian Public Health.” Value in Health 19 (3): A289–A290. https://doi.org/10.1016/j.jval.2016.03.749.

Harvard

Ibrahim, S. (2016) ‘Marketing Authorization of Medicines Approved In Eu Via “Adaptive Pathway”: Consequences on The Egyptian Public Health’, Value in Health, 19(3), pp. A289–A290. doi:10.1016/j.jval.2016.03.749.

IEEE

S. Ibrahim, “Marketing Authorization of Medicines Approved In Eu Via “Adaptive Pathway”: Consequences on The Egyptian Public Health,” Value in Health, vol. 19, no. 3, pp. A289–A290, 2016, doi: 10.1016/j.jval.2016.03.749.

BibTeX

@article{ibrahim2016marketing,
  title     = {{Marketing Authorization of Medicines Approved In Eu Via “Adaptive Pathway”: Consequences on The Egyptian Public Health}},
  author    = {Ibrahim, S.R.},
  journal   = {Value in Health},
  year      = {2016},
  volume    = {19},
  number    = {3},
  pages     = {A289--A290},
  doi       = {10.1016/j.jval.2016.03.749},
  url       = {https://doi.org/10.1016/j.jval.2016.03.749}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy

  • drug approval
  • drug regulation
  • benefit-risk balance
  • unmet medical needs
  • pharmacovigilance
  • off-label drug use
  • performance-based pay
  • reimbursement policy

Work with this paper

Most-cited papers in Economics, Econometrics and Finance

All highly cited Economics, Econometrics and Finance papers

Questions about this paper

How do I cite this paper in APA style?

Ibrahim, S. (2016). Marketing Authorization of Medicines Approved In Eu Via “Adaptive Pathway”: Consequences on The Egyptian Public Health. Value in Health, 19(3), A289–A290. https://doi.org/10.1016/j.jval.2016.03.749

How many times has this paper been cited?

0 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Value in Health: sign in and open the full text from this page.

Who wrote this paper?

S.R. Ibrahim.

What is the DOI of this paper?

10.1016/j.jval.2016.03.749, permanently at https://doi.org/10.1016/j.jval.2016.03.749. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.